“Unraveling the Legal Labyrinth: Can AI Revolutionize Pharma Without Copyright Catastrophes?”
McSpiritt also cites reputational risk, arguing pharma and clinical organizations rely on trust — both from industry partners and the public. If a company is found to be using copyrighted, patented, or confidential materials without permission, it could face backlash, lose future collaboration opportunities, and erode public confidence in its treatments.
Overall, ensuring compliance and using curated high-quality datasets from the outset not only prevent legal and reputational challenges, but also improve AI-driven research outcomes as Marmanis notes.
